Cargando…

Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment

Rheumatoid arthritis (RA) patients are at high risk of cardiovascular (CV) events, and the chronic inflammatory state may generate quantitative and qualitative changes in lipoprotein fractions. The anti-IL-6 receptor tocilizumab (TCZ), even if effective in inflammation and joint damage prevention, d...

Descripción completa

Detalles Bibliográficos
Autores principales: Cacciapaglia, Fabio, Anelli, Maria Grazia, Rinaldi, Angela, Fornaro, Marco, Lopalco, Giuseppe, Scioscia, Crescenzio, Lapadula, Giovanni, Iannone, Florenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204176/
https://www.ncbi.nlm.nih.gov/pubmed/30405318
http://dx.doi.org/10.1155/2018/2453265
_version_ 1783366002731384832
author Cacciapaglia, Fabio
Anelli, Maria Grazia
Rinaldi, Angela
Fornaro, Marco
Lopalco, Giuseppe
Scioscia, Crescenzio
Lapadula, Giovanni
Iannone, Florenzo
author_facet Cacciapaglia, Fabio
Anelli, Maria Grazia
Rinaldi, Angela
Fornaro, Marco
Lopalco, Giuseppe
Scioscia, Crescenzio
Lapadula, Giovanni
Iannone, Florenzo
author_sort Cacciapaglia, Fabio
collection PubMed
description Rheumatoid arthritis (RA) patients are at high risk of cardiovascular (CV) events, and the chronic inflammatory state may generate quantitative and qualitative changes in lipoprotein fractions. The anti-IL-6 receptor tocilizumab (TCZ), even if effective in inflammation and joint damage prevention, determined significant alterations to RA patients' lipid levels in randomized controlled trials, but real-world data are lacking. We evaluated the changes in lipid fraction levels and disease activity in a longitudinal cohort of RA patients on long-term treatment with tocilizumab (TCZ) in a community setting. We retrospectively selected 40 naïve-biologic RA patients on treatment with intravenous TCZ compared to 20 RA patients on methotrexate treatment as the control group. Total cholesterol (Tot-Chol), low-density lipoproteins (LDL), high-density lipoprotein (HDL), and triglyceride (TG) levels were measured at the baseline and at 12, 24, and 52 weeks thereafter. At the same points, 28-joint disease activity score (DAS28), clinical disease activity index (CDAI), and EULAR clinical responses were also assessed. During the first 24 weeks, we observed in TCZ-treated patients a progressive statistically significant (p < 0.001) increase in Tot-Chol, LDL, HDL, and TG, which returned close to the baseline at 52 weeks. But no changes in the lipid-related CV risk indices Tot-Chol/HDL and LDL/HDL ratios and the atherogenic index (log(10) TG/HDL) were detectable. Notably, we observed a statistically significant negative correlation between changes in lipid fractions and DAS28 or CDAI. The prolonged treatment with TCZ was associated to a transient increase in cholesterol's fractions during the first 6 months of treatment, with inverse correlation to disease activity, but with no impact on surrogate lipid indices of atherogenic risk. These findings may aid clinicians in interpreting the RA patient's lipid profile in daily clinical practice.
format Online
Article
Text
id pubmed-6204176
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-62041762018-11-07 Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment Cacciapaglia, Fabio Anelli, Maria Grazia Rinaldi, Angela Fornaro, Marco Lopalco, Giuseppe Scioscia, Crescenzio Lapadula, Giovanni Iannone, Florenzo Mediators Inflamm Research Article Rheumatoid arthritis (RA) patients are at high risk of cardiovascular (CV) events, and the chronic inflammatory state may generate quantitative and qualitative changes in lipoprotein fractions. The anti-IL-6 receptor tocilizumab (TCZ), even if effective in inflammation and joint damage prevention, determined significant alterations to RA patients' lipid levels in randomized controlled trials, but real-world data are lacking. We evaluated the changes in lipid fraction levels and disease activity in a longitudinal cohort of RA patients on long-term treatment with tocilizumab (TCZ) in a community setting. We retrospectively selected 40 naïve-biologic RA patients on treatment with intravenous TCZ compared to 20 RA patients on methotrexate treatment as the control group. Total cholesterol (Tot-Chol), low-density lipoproteins (LDL), high-density lipoprotein (HDL), and triglyceride (TG) levels were measured at the baseline and at 12, 24, and 52 weeks thereafter. At the same points, 28-joint disease activity score (DAS28), clinical disease activity index (CDAI), and EULAR clinical responses were also assessed. During the first 24 weeks, we observed in TCZ-treated patients a progressive statistically significant (p < 0.001) increase in Tot-Chol, LDL, HDL, and TG, which returned close to the baseline at 52 weeks. But no changes in the lipid-related CV risk indices Tot-Chol/HDL and LDL/HDL ratios and the atherogenic index (log(10) TG/HDL) were detectable. Notably, we observed a statistically significant negative correlation between changes in lipid fractions and DAS28 or CDAI. The prolonged treatment with TCZ was associated to a transient increase in cholesterol's fractions during the first 6 months of treatment, with inverse correlation to disease activity, but with no impact on surrogate lipid indices of atherogenic risk. These findings may aid clinicians in interpreting the RA patient's lipid profile in daily clinical practice. Hindawi 2018-10-14 /pmc/articles/PMC6204176/ /pubmed/30405318 http://dx.doi.org/10.1155/2018/2453265 Text en Copyright © 2018 Fabio Cacciapaglia et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Cacciapaglia, Fabio
Anelli, Maria Grazia
Rinaldi, Angela
Fornaro, Marco
Lopalco, Giuseppe
Scioscia, Crescenzio
Lapadula, Giovanni
Iannone, Florenzo
Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment
title Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment
title_full Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment
title_fullStr Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment
title_full_unstemmed Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment
title_short Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment
title_sort lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204176/
https://www.ncbi.nlm.nih.gov/pubmed/30405318
http://dx.doi.org/10.1155/2018/2453265
work_keys_str_mv AT cacciapagliafabio lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment
AT anellimariagrazia lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment
AT rinaldiangela lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment
AT fornaromarco lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment
AT lopalcogiuseppe lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment
AT sciosciacrescenzio lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment
AT lapadulagiovanni lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment
AT iannoneflorenzo lipidsandatherogenicindicesfluctuationinrheumatoidarthritispatientsonlongtermtocilizumabtreatment